Page 153 - CW E-Magazine (17-9-2024)

Top Stories Pharmaceuticals

COURT BATTLE NEW LEADER

FMC granted a temporary restraining order against Enzene appoints new site lead for its US biomanu-

Sharda Cropchem’s US arm for patent infringement facturing facility

US-based agricultural sciences The court order is part of an ongo- this order will not affect the company’s Enzene Biosciences, a Pune-based facturing projects and expand to add expertise and fl exible continuous manu-
company, FMC Corporation, has an- ing FMC lawsuit alleging that Sharda business signifi cantly, as the product CDMO (contract development and further bioreactor capacity, employing facturing capabilities fi rst developed at
nounced that the United States Dis- infringes on the company’s US patents accounts for less than 0.2% of its total US manufacturing organisation) and a a workforce of 300 by the end of 2025. the company’s facility in Pune.
trict Court for the Eastern District of covering insecticide products contain- sales. The court has required the litigant subsidiary of Alkem Laboratories,
Pennsylvania has granted a temporary ing bifenthrin and zeta-cypermethrin. company to post a $500,000 bond as has announced the appointment of Established in 2015, Enzene Bio- “Existing and new customers see
restraining order against Sharda USA FMC sells a premix of bifenthrin and compensation to Sharda Cropchem. Mr. Norm Stoffregen as SVP, site sciences has grown from a 25,000 the powerful opportunities that conti-
LLC, a subsidiary of Mumbai-based zeta-cypermethrin insecticides in the head, and head of biologics manufac- square feet facility in Pune, to a global nuous biologics technology brings,
Sharda Cropchem. The order restrains US under the brand ‘Hero’ insecticide Mr. Bubna also expects a positive turing at the company’s new $50-mn organisation with R&D and clini- not least by providing fl exibility and
Sharda from importing, marketing, that is protected by the asserted patents. trend in agrochemical prices. While the manufacturing facility in Hopewell, cal-scale GMP facilities in India and lowering the cost of manufacturing,”
advertising, selling or distributing any FMC’s lawsuit also alleges that Sharda’s prices of certain products had plum- near Princeton, New Jersey, USA. the US. commented Mr. Stoffregen. “We are
premix products containing bifenthrin product label for ‘Winner’ misap- meted by up to 75%, there is now a already in discussion with biopharma
and cyano-pyrethroids that are covered propriated FMC’s copyrighted product gradual improvement, he noted. “Prices As well as taking responsibility The company’s Princeton site fea- companies keen to progress pro-
by FMC’s patents. This includes label for ‘Hero’. are becoming more favourable and get- for Enzene’s global biologics busi- tures EnzeneX, the company’s contin- grammes for the domestic market and
Sharda’s ‘Winner’ insecticide product ting towards normalcy. The process of ness, Mr. Stoffregen will lead the uous manufacturing platform, as well beyond, and in the next 18-months
containing bifenthrin and zeta-cyper- Mr. R. V. Bubna, Chairman and Man- recovery will take time, but it is on the fi nal stages of work to commission as development and quality laborato- we expect to ramp up our production
methrin. aging Director of Sharda Cropchem, said way up,” Mr. Bubna commented. the 54,000-square-foot facility. He ries, warehousing, frozen storage and capacity and capabilities, and grow
will then lead ongoing operations at cell banking. When complete, it will our pipeline of work with biotech and
AMBITIOUS TARGET the site, where the company intends to complement Enzene’s global network pharma companies in early phases of
India aiming for 10 semiconductor fabs in 10 years transfer-in existing customers’ manu- and benefi t from process development development.”
NEW AVENUES
India aspires to have 10 semicon- “We will always be engaged with plants. Mr. Tripathi said that all the
ductor manufacturing plants in 10 years the industry but the nature of engage- proposals are at different stages of Natco Pharma’s Canadian arm invests $8-mn in eGenesis
but the nature of support from the govern- ments may differ. 10 years down the approval. He said that the government
ment may vary based on the deve- line there will be projects that will be has approved fi ve projects entailing Natco Pharma’s wholly-owned Cana- Vice-Chairman and CEO, Natco Pharma, The eGenesis Genome Engineering
lopment in the industry, according to operational, producing semiconductors, investment of Rs. 1.52 lakh-crore. dian subsidiary, Natco Pharma (Canada) said in a release. In March 2024, and Production (EGEN) Platform is the
Mr. Akash Tripathi, CEO of the India the ecosystem will be developed, then Inc., has invested $8-mn in the US-based eGenesis announced the world’s fi rst only technology of its kind to compre-
Semiconductor Mission (ISM). things will be different. Aspiration- The government is also focusing on biotechnology company, eGenesis Inc. porcine kidney transplant in a living hensively address cross-species mole-
wise, we would like to have 10 fabs,” getting other companies such as raw patient. The transplant was authorised cular incompatibilities and viral risk via
He said while setting up ISM, it was Mr. Tripathi said. material suppliers, gas companies and “We are excited to get involved with by the US Food & Drug Administration genetic engineering to improve the lives
envisioned to get two or three semi- other vendors of the semiconductor eGenesis Inc with respect to their pio- (FDA) under the Expanded Access pathway. of patients in need of a transplant.
neering work in xenotransplantation.
conductor manufacturing plants, two or The government has received 20 ecosystem to India, apart from working We agree with the vision of eGenesis Genome engineering Cambridge-based eGenesis is
three display fabs and various com- proposals for setting up semiconduc- to get the chip fabrication and packag- that xenotransplantation technology has eGenesis is pioneering a genome engi- focused on using its multiplex gene edit-
pound semiconductors. tor units including the chip packaging ing units, he said.
the potential to end the global transplant neering-based approach in the develop- ing and genome engineering platform
DKSH India gets ‘Great Place To Work’ certifi cation shortage and transforming the treatment ment of safe and effective transplantable to transform solid organ and therapeutic
of organ failure by eliminating waitlist organs to end the global organ shortage cell transplantation for the treatment of
for the second time mortality,” Mr. Rajeev Nannapaneni, and transform the treatment of organ failure. serious diseases.
Chemical distribution fi rm, DKSH second year of being recognised among culture, including trust, leadership, and ‘Pharma Manufacturing & Automation Convention 2024’
India, has announced its reaccreditation the top workplaces,” the company more, it added. “Our employees are the
as a ‘Great Place To Work’, refl ecting informed in a press note. cornerstone of our success, and their to be held in Hyderabad in Oct
an impressive employee satisfaction high level of satisfaction refl ects our
rate of 88%. “The certifi cation, awarded The recognition is the result of a commitment to their well-being,” said The ‘6th Annual Pharma Manufactur- nence Business Media. The fi rst day of integrity in manufacturing processes, and
based on a comprehensive anonymous thorough assessment and a compre- Mr. Vishal Jawale, Managing Director ing & Automation Convention 2024’ will the conference will focus on topics such compliance requirements. Discussions
survey, marks a signifi cant milestone hensive survey of employees, which and Country Management Head, be held in Hyderabad on October 17-18, as Industry 4.0 implementation strategies, will also centre around harnessing the
for DKSH India as it celebrates its evaluates various aspects of workplace DKSH India. 2024, according to the organiser, Emi- advanced automation technologies, data power of robotics, artifi cial intelligence,

152 Chemical Weekly September 17, 2024 Chemical Weekly September 17, 2024 153

Contents Index to Advertisers Index to Products Advertised